1. Home
  2. HALO vs RGEN Comparison

HALO vs RGEN Comparison

Compare HALO & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Halozyme Therapeutics Inc.

HALO

Halozyme Therapeutics Inc.

HOLD

Current Price

$63.51

Market Cap

7.4B

Sector

Health Care

ML Signal

HOLD

Logo Repligen Corporation

RGEN

Repligen Corporation

HOLD

Current Price

$165.14

Market Cap

8.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HALO
RGEN
Founded
1998
1981
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.4B
8.2B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
HALO
RGEN
Price
$63.51
$165.14
Analyst Decision
Buy
Buy
Analyst Count
12
10
Target Price
$73.33
$170.90
AVG Volume (30 Days)
2.7M
826.7K
Earning Date
11-03-2025
10-28-2025
Dividend Yield
N/A
N/A
EPS Growth
56.68
N/A
EPS
4.74
0.03
Revenue
$1,242,852,000.00
$707,890,000.00
Revenue This Year
$32.47
$17.84
Revenue Next Year
$24.31
$12.57
P/E Ratio
$13.37
$5,343.41
Revenue Growth
31.19
11.74
52 Week Low
$46.26
$102.97
52 Week High
$79.50
$182.52

Technical Indicators

Market Signals
Indicator
HALO
RGEN
Relative Strength Index (RSI) 33.96 58.40
Support Level $61.70 $161.67
Resistance Level $74.25 $170.40
Average True Range (ATR) 2.52 5.85
MACD -0.97 0.09
Stochastic Oscillator 13.39 67.15

Price Performance

Historical Comparison
HALO
RGEN

About HALO Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

Share on Social Networks: